Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
GENILGen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration and licensing agreement with Sulfateq BV for the development and commercialization of the original molecule SUL-238 as a unique treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey. Address: Mustafa Kemal Mahallesi 2119.Sk. No:3, Çankaya, Turkey, 06520
Analytics
Zielpreis von Wall Street
–KGV
36.7871Dividendenrendite
0.4 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen GENIL
Dividenden-Analyse GENIL
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
20 %Verlauf der Dividende GENIL
Bewertung der Aktie GENIL
Finanzen GENIL
Ergebnisse | 2019 | Dynamik |